Organisation paid for research Program year 2025 Source: CMS Open Payments

Tyler Cardiovascular Consultants

Neither a doctor nor a teaching hospital

Research payments

$1,064,190

155 payments

Through program year 2025, Tyler Cardiovascular Consultants is reported as receiving $1,064,190 in research payments, across 155 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $111,730 5
2024 Research $48,202 4
2023 Research $163,583 20
2022 Research $166,188 29
2021 Research $192,342 43
2020 Research $203,785 29
2019 Research $178,359 25

Breakdown

Who paid Research payments · program years 2019–2025
  1. LivaNova USA, Inc. $310,207 58 payments
  2. Merck Sharp & Dohme Corporation $198,450 15 payments
  3. Novartis Pharmaceuticals Corporation $172,501 8 payments
  4. Abbott Laboratories $170,060 39 payments
  5. CVRx, Inc. $140,275 32 payments
  6. Amgen Inc. $70,196 2 payments
  7. Organon LLC $2,500 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. ANTHEM HFrEF $310,207 58 payments
  2. A Pivotal Phase 3 Randomized, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of the sGC Stimulator Vericiguat,MK-1242 in Adults With Chronic Heart Failure With Reduced Ejection Fraction $164,694 13 payments
  3. A Randomized, Controlled, Multicenter, Open-Label Trial Comparing A Post-Discharge Care Pathway Involving Aggressive LDL-C Management With Inclisiran With Usual Care in Patients With A Recent Acute Coronary Syndrome $149,097 5 payments
  4. Study name not reported $140,275 32 payments
  5. A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing Olpasiran Use to Prevent First Major Cardiovascular Events in Participants With Elevated Lipoprotein(a) $54,296 1 payment
  6. XIENCE 28 USA Study $43,750 4 payments
  7. DAPT study $27,515 3 payments
  8. A Pivotal Phase 3 Randomized, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of the sGC Stimulator Vericiguat,MK-1242 in Adults With Chronic Heart Failure With Reduced Ejection Fraction $26,469 1 payment
  9. Observational Registry of Treatment Patterns in US Heart Failure Patients With Reduced Ejection Fraction $23,404 3 payments
  10. A Clinical Evaluation of Absorb BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects With de Novo Native Coronary Artery Lesions. $19,788 5 payments
What the money was spent on Research payments · program years 2019–2025
  1. Patient care $2,500 1 payment

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record